分析师们持续买入Fractyl Health的评级，称其增长和临床进展，尽管没有盈利。 Analysts keep buy ratings on Fractyl Health, citing growth and clinical progress despite no profits.

分析家仍然对分体健康(GUTS)进行购买评级,并援引其创新做法,通过尽量减少侵入性的程序治疗胃肠道和代谢疾病。 Analysts maintain buy ratings on Fractyl Health (GUTS), citing its innovative approach to treating gastrointestinal and metabolic diseases through minimally invasive procedures. 尽管股票业绩好坏参半,缺乏盈利能力,但该公司收入增长强劲,临床数据扩大,临床采用率增加,这些都支持长期乐观。 Despite mixed stock performance and lack of profitability, the company’s strong revenue growth, expanding clinical data, and increasing clinical adoption support long-term optimism. 一些公司略微提高了价格目标,分析家强调,即将作出的监管决定和商业推出进展是近期关键的催化剂。 Price targets have been slightly raised by some firms, with analysts highlighting upcoming regulatory decisions and commercial rollout progress as key near-term catalysts. 上季度没有降级,反映出对公司潜力的持续信心。 No downgrades have been issued in the past quarter, reflecting continued confidence in the company’s potential.